Table 1.

Antiviral efficacy and cytotoxicity of PF-00835231 versus remdesivir on A549+ACE2 cells

USA-WA1/2020
time	EC50 μM	(95% CI)	p value*	p value**	EC90 μM	(95% CI)	CC50 μM
PF-00835231
24 hpi	0.221	0.137 −0.356			0.734	0.391–1.38	> 10
48 hpi	0.158	0.0795 – 0.314			0.439	0.380–0.508	> 10
remdesivir
24 hpi	0.442	0.240–0.814	0.002		1.19	0.622–2.28	> 10
48 hpi	0.238	0.122–0.436	0.035		0.529	0.534–0.656	> 10
USA/NYU-VC-003/2020
time	EC50 μM	(95% CI)	p value*	p value**	EC90 μM	(95% CI)	CC50 μM
PF-00835231
24 hpi	0.184	0.016–0.377		0.307	0.591	0.534–0.654	> 10
remdesivir
24 hpi	0.238	0.200–0.400	0.028	0.024	0.589	0.416–0.834	> 10

^*EC50 of remdesivir vs EC50 of PF-00835231

^**EC50 of drug vs EC50 of same drug for USA-WA1/2020